Neuralgia News and Research

RSS

Neuralgia is pain in one or more nerves that occurs without stimulation of pain receptor (nociceptor) cells. Neuralgia pain is produced by a change in neurological structure or function rather than by the excitation of pain receptors that causes nociceptive pain.

Brain surgeon partners with NASA's JPL to design high-tech surgical instruments

Internationally renowned brain surgeon Hrayr Shahinian, M.D., a pioneer in minimally invasive brain surgery, has announced that he is teaming with scientists and technologists at NASA's Jet Propulsion Laboratory in Pasadena, Calif., to design the next generation of high-tech surgical instruments - technology that also will be useful for planetary exploration.

2 Feb 2011

Endo Pharmaceutical partners receive Paragraph IV Certification for generic version of LIDODERM

Endo Pharmaceuticals announced today that its partners, Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, have received a Paragraph IV Certification Notice from Mylan Technologies advising of the filing of an Abbreviated New Drug Application for a generic version of LIDODERM.

31 Jan 2011

FDA approves GRALISE Tablets for treatment of PHN

Depomed, Inc. today announced that US FDA has approved GRALISE (gabapentin) Tablets for once-daily treatment of post-herpetic neuralgia, which is pain following healing of the rash associated with shingles.

29 Jan 2011

Alliqua completes transdermal pain patch initial study for treatment of PHN

Alliqua, an advanced biomedical products company focused on the development and manufacturing of proprietary drug delivery and liver health technologies, announced today the successful completion of its initial study for the transdermal pain patch project.

20 Jan 2011

Neuros Medical announces initial feasibility study results of HFAC Nerve Block technology

Neuros Medical, Inc., a medical device company announced today initial feasibility study results of their patented high frequency alternating current (HFAC) Nerve Block technology from their first patient. The study is a short-term, 30-day test per patient, focusing on chronic residual limb pain. Nearly one million patients suffer from chronic residual limb pain in the U.S.

20 Jan 2011

Less than 7% of U.S. seniors get shingles vaccination

Although a vaccine to prevent shingles has been available since 2006, less than 7 percent of U.S. seniors — the demographic most frequently affected by the disease — chose to receive the vaccination as of 2008, finds a new study from the Centers for Disease Control and Prevention (CDC).

11 Jan 2011

Top-line results from Inhibitex's FV-100 Phase II clinical trial for treatment of shingles

Inhibitex, Inc. today reported top-line safety and efficacy data from its Phase II clinical trial of FV-100, an oral antiviral compound being developed to treat herpes zoster, more commonly referred to as shingles. The study was the first clinical trial to assess the antiviral activity of FV-100, included 350 shingles patients and compared two once-daily doses of FV-100 (200 mg and 400 mg) to an active control, valacyclovir, one of the most commonly-used antiviral drugs to treat shingles.

14 Dec 2010

Study comparing subcutaneous, intravenous administration of VELCADE in relapsed MM patients presented at ASH

Millennium: The Takeda Oncology Company today reported results from a randomized, international Phase III clinical trial comparing subcutaneous and intravenous administration of VELCADE (bortezomib) in patients with relapsed multiple myeloma. These data were presented at the 52nd annual meeting of the American Society of Hematology, held December 4-7 in Orlando, Florida.

8 Dec 2010

CMS grants Qutenza J-code to NeurogesX

NeurogesX, Inc. a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced that the Centers for Medicare and Medicaid Services (CMS) has granted a unique, Level II Health Care Common Procedural Coding System (Level II HCPCS), commonly referred to as a J-code, for Qutenza (capsaicin) 8% patch.

19 Nov 2010

CDC data: Adults remain unvaccinated against preventable infectious illnesses

New data from the Centers for Disease Control and Prevention (CDC) show that adults remain largely unvaccinated against preventable infectious illnesses.

18 Nov 2010

Pharmigene receives patent for methods to detect genetic alleles in SJS and TENS

Pharmigene, a leader in advancing personalized medicine and reducing severe adverse reactions to drugs through genetic-based diagnostic solutions, announced it has been granted patents in the United States, Europe, Australia, Singapore and Taiwan. The patents cover methods to detect the presence of key genetic alleles in individual patients being considered for treatment with drugs that have been linked to the development of adverse drug reactions including Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

17 Nov 2010

XenoPort third quarter net loss decreases to $19.9 million

XenoPort, Inc. announced today financial results for the third quarter and nine months ended September 30, 2010. Revenues for the third quarter were $0.4 million, compared to $0.4 million for the same period in 2009. Net loss for the third quarter was $19.9 million, compared to a net loss of $24.4 million for the same period in 2009.

8 Nov 2010

Aestus receives $244,000 grant from QTDP program

Today Aestus Therapeutics, Inc. announced that it has been awarded a $244,000 grant from the U.S. Government's Qualifying Therapeutic Discovery Project program.

4 Nov 2010

Integra launches XKnife 5 Stereotactic Radiosurgery and Radiotherapy Treatment Planning Software

Integra LifeSciences Holdings Corporation announced today the launch of its XKnife® 5 Stereotactic Radiosurgery and Radiotherapy Treatment Planning Software. The XKnife® 5 Stereotactic Radiosurgery and Radiotherapy Treatment Planning Software is part of Integra's XKnife® System and is indicated for Stereotactic Radiosurgery (SRS) and Stereotactic Radiotherapy (SRT).

3 Nov 2010

NeurogesX initiates NGX-1998 Phase 2 study in postherpetic neuralgia

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced dosing of the first patient in its Phase 2 clinical study of NGX-1998, a liquid formulation of high-concentration capsaicin, in patients with postherpetic neuralgia (PHN).

3 Nov 2010

Pfizer announces approval of Lyrica capsules for peripheral neuropathic pain

Pfizer Inc announced that the Japanese Ministry of Health, Labour and Welfare approved Lyrica (pregabalin) capsules for the treatment of peripheral neuropathic pain. This follows the recent approval in Japan of Lyrica for the treatment of postherpetic neuralgia on April 16, 2010. Lyrica is the first medication approved for peripheral neuropathic pain in Japan where it is co-promoted with Eisai Co., Ltd.

29 Oct 2010

Stereotactic radiation effective for trigeminal neuralgia

Stereotactic radiation is an effective, long-term treatment for trigeminal neuralgia: a painful condition that occurs with increased frequency in patients with multiple sclerosis (MS). Radiation is noninvasive and has less negative side effects than other treatments, according to the longest follow-up in a study of its kind presented October 31, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

NeurogesX plans U.S. label expansion for Qutenza in HIV-associated neuropathy

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced plans to pursue a U.S. label expansion for Qutenza® (capsaicin) 8% patch to include patients with painful HIV-associated neuropathy (HIV-AN, also referred to as HIV-distal sensory polyneuropathy (HIV-DSP)).

19 Oct 2010

Enrollment complete in Inhibitex's FV-100 Phase II clinical trial in shingles patients

Inhibitex, Inc., announced today that it has completed enrollment in a Phase II clinical trial of FV-100 in shingles (herpes zoster) patients. The objectives of the trial are to further evaluate the safety of FV-100 and its potential therapeutic benefit in reducing the severity and duration of shingles-associated pain, the incidence of post herpetic neuralgia (PHN), and the time to heal shingles-related lesions.

15 Oct 2010

Stanford Cancer Center announces successful treatment of 5,000th patient with CyberKnife system

When Lori Brownell's first tumor appeared − on her left carotid artery − it was surgically removed, leaving an inches-long incision to heal. It was eight years before the feeling returned to that side of her neck, and for a time, she couldn't drive because she couldn't turn her head far enough.

21 Sep 2010